Key Takeaways
- • The University of Michigan's $17.9 billion endowment committed $75 million to Hydrazine Capital IV, Sam Altman's venture capital firm's fourth fund, in a transaction completed before end of June 2023.
- • Hydrazine Capital IV is structured as a small, focused fund with the University of Michigan as its sole outside investor, according to Dan Feder, senior managing director of investments at the endowment.
- • This represents the second institutional commitment from the University of Michigan to Altman-managed funds; the endowment has also invested directly in OpenAI and its corporate venture vehicle.
- • The fund was disclosed to the Securities and Exchange Commission in March 2023, with the $75 million investment occurring sometime between March and June of that year.
- • OpenAI confirmed Altman's venture activities are disclosed to the board and managed through a formal conflict-of-interest process, with the company characterizing his VC work as consuming only a small fraction of his time as CEO.
Summary
The University of Michigan's endowment invested $75 million in Hydrazine Capital IV, the fourth fund managed by Sam Altman's venture capital firm, earlier in 2023. The investment was completed sometime before the end of June, following the fund's SEC disclosure in March. According to Dan Feder, senior managing director of investments at Michigan's endowment, Hydrazine IV operates as a specialized, small-scale fund with the University of Michigan as its only external limited partner, describing it as "an extension of our ongoing investment strategies."
The University of Michigan endowment, which manages $17.9 billion in assets, has built a material relationship with Altman and his investment vehicles. Beyond the Hydrazine Capital IV commitment, the endowment has made direct investments in OpenAI and in OpenAI's corporate venture fund. The endowment declined to disclose specific details regarding Hydrazine IV's exact fund size, investment thesis, or sector focus. Similarly, Altman, Hydrazine Capital, and OpenAI declined to provide additional commentary on the investment structure or rationale.
In response to inquiries, OpenAI emphasized that Altman maintains full transparency with the company's board regarding his venture capital investments and operates under formal processes for managing potential conflicts of interest. The company's statement characterized Altman's VC activities as occupying only a minor portion of his time relative to his primary responsibilities as CEO. The restriction of Hydrazine IV's investor base to a single outside limited partner—the University of Michigan—is an unusual structure in venture capital, suggesting either a highly specialized investment focus or a relationship-driven arrangement between the institution and Altman's firm.
The University of Michigan endowment, which manages $17.9 billion in assets, has built a material relationship with Altman and his investment vehicles. Beyond the Hydrazine Capital IV commitment, the endowment has made direct investments in OpenAI and in OpenAI's corporate venture fund. The endowment declined to disclose specific details regarding Hydrazine IV's exact fund size, investment thesis, or sector focus. Similarly, Altman, Hydrazine Capital, and OpenAI declined to provide additional commentary on the investment structure or rationale.
In response to inquiries, OpenAI emphasized that Altman maintains full transparency with the company's board regarding his venture capital investments and operates under formal processes for managing potential conflicts of interest. The company's statement characterized Altman's VC activities as occupying only a minor portion of his time relative to his primary responsibilities as CEO. The restriction of Hydrazine IV's investor base to a single outside limited partner—the University of Michigan—is an unusual structure in venture capital, suggesting either a highly specialized investment focus or a relationship-driven arrangement between the institution and Altman's firm.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.